These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15994456)

  • 1. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine.
    Peng X; Chen B; Lim CC; Sawyer DB
    Mol Interv; 2005 Jun; 5(3):163-71. PubMed ID: 15994456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and cellular mechanisms of anthracycline cardiotoxicity.
    Chen B; Peng X; Pentassuglia L; Lim CC; Sawyer DB
    Cardiovasc Toxicol; 2007; 7(2):114-21. PubMed ID: 17652815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
    de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
    Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
    Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
    Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
    Schneider JW; Chang AY; Rocco TP
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer therapy induced cardiotoxicity: review of the literature.
    Geiger S; Lange V; Suhl P; Heinemann V; Stemmler HJ
    Anticancer Drugs; 2010 Jul; 21(6):578-90. PubMed ID: 20375725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
    J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity of antitumor drugs.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2008 May; 21(5):978-89. PubMed ID: 18376852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
    Morris PG; Hudis CA
    J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
    Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
    Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity of cytotoxic drugs.
    Schimmel KJ; Richel DJ; van den Brink RB; Guchelaar HJ
    Cancer Treat Rev; 2004 Apr; 30(2):181-91. PubMed ID: 15023436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
    Gianni L; Salvatorelli E; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracyclines and trastuzumab; getting to the heart of the matter: when getting to the heart is the matter.
    Morris PG; Hudis CA
    Breast Cancer Res Treat; 2011 Jun; 127(2):585-6. PubMed ID: 18791822
    [No Abstract]   [Full Text] [Related]  

  • 16. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
    Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
    Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
    Suter TM; Cook-Bruns N; Barton C
    Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Trastuzumab (Herceptin)].
    Tokuda Y; Suzuki Y; Saitou Y; Ohta M; Tajima T
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):645-52. PubMed ID: 11977556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity.
    Walker JR; Sharma A; Lytwyn M; Bohonis S; Thliveris J; Singal PK; Jassal DS
    J Am Soc Echocardiogr; 2011 Jun; 24(6):699-705. PubMed ID: 21353471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
    Yuste L; Montero JC; Esparís-Ogando A; Pandiella A
    Cancer Res; 2005 Aug; 65(15):6801-10. PubMed ID: 16061662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.